vs

Side-by-side financial comparison of ARTESIAN RESOURCES CORP (ARTNA) and Ginkgo Bioworks Holdings, Inc. (DNA). Click either name above to swap in a different company.

Ginkgo Bioworks Holdings, Inc. is the larger business by last-quarter revenue ($33.4M vs $28.0M, roughly 1.2× ARTESIAN RESOURCES CORP). On growth, ARTESIAN RESOURCES CORP posted the faster year-over-year revenue change (4.3% vs -23.8%). ARTESIAN RESOURCES CORP produced more free cash flow last quarter ($-7.9M vs $-47.7M). Over the past eight quarters, ARTESIAN RESOURCES CORP's revenue compounded faster (6.8% CAGR vs -6.2%).

Artesian Resources Corp is a US-headquartered regulated water utility and wastewater service provider, primarily serving residential, commercial, industrial and municipal customers across Delaware. It focuses on delivering safe, reliable drinking water supply and sustainable wastewater treatment solutions to local communities.

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

ARTNA vs DNA — Head-to-Head

Bigger by revenue
DNA
DNA
1.2× larger
DNA
$33.4M
$28.0M
ARTNA
Growing faster (revenue YoY)
ARTNA
ARTNA
+28.2% gap
ARTNA
4.3%
-23.8%
DNA
More free cash flow
ARTNA
ARTNA
$39.8M more FCF
ARTNA
$-7.9M
$-47.7M
DNA
Faster 2-yr revenue CAGR
ARTNA
ARTNA
Annualised
ARTNA
6.8%
-6.2%
DNA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ARTNA
ARTNA
DNA
DNA
Revenue
$28.0M
$33.4M
Net Profit
$4.1M
Gross Margin
Operating Margin
20.6%
-211.9%
Net Margin
14.8%
Revenue YoY
4.3%
-23.8%
Net Profit YoY
7.5%
EPS (diluted)
$0.39
$-1.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARTNA
ARTNA
DNA
DNA
Q4 25
$28.0M
$33.4M
Q3 25
$30.5M
$38.8M
Q2 25
$28.5M
$49.6M
Q1 25
$25.9M
$48.3M
Q4 24
$26.9M
$43.8M
Q3 24
$29.1M
$89.0M
Q2 24
$27.4M
$56.2M
Q1 24
$24.5M
$37.9M
Net Profit
ARTNA
ARTNA
DNA
DNA
Q4 25
$4.1M
Q3 25
$7.0M
$-80.8M
Q2 25
$6.3M
$-60.3M
Q1 25
$5.4M
$-91.0M
Q4 24
$3.8M
Q3 24
$6.8M
$-56.4M
Q2 24
$5.3M
$-217.2M
Q1 24
$4.4M
$-165.9M
Operating Margin
ARTNA
ARTNA
DNA
DNA
Q4 25
20.6%
-211.9%
Q3 25
28.3%
-231.8%
Q2 25
27.5%
-132.1%
Q1 25
21.4%
-184.1%
Q4 24
21.0%
-236.3%
Q3 24
29.5%
-62.0%
Q2 24
26.3%
-396.7%
Q1 24
19.2%
-469.1%
Net Margin
ARTNA
ARTNA
DNA
DNA
Q4 25
14.8%
Q3 25
22.8%
-207.9%
Q2 25
22.0%
-121.6%
Q1 25
21.0%
-188.2%
Q4 24
14.3%
Q3 24
23.4%
-63.3%
Q2 24
19.4%
-386.4%
Q1 24
18.0%
-437.3%
EPS (diluted)
ARTNA
ARTNA
DNA
DNA
Q4 25
$0.39
$-1.41
Q3 25
$0.68
$-1.45
Q2 25
$0.61
$-1.10
Q1 25
$0.53
$-1.68
Q4 24
$0.37
$-1.91
Q3 24
$0.66
$-1.08
Q2 24
$0.52
$-4.23
Q1 24
$0.43
$-3.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARTNA
ARTNA
DNA
DNA
Cash + ST InvestmentsLiquidity on hand
$52.0K
$422.6M
Total DebtLower is stronger
$176.4M
Stockholders' EquityBook value
$249.9M
$508.6M
Total Assets
$851.2M
$1.1B
Debt / EquityLower = less leverage
0.71×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARTNA
ARTNA
DNA
DNA
Q4 25
$52.0K
$422.6M
Q3 25
$705.0K
$495.5M
Q2 25
$349.0K
$559.4M
Q1 25
$3.7M
$325.3M
Q4 24
$1.1M
$561.6M
Q3 24
$10.7M
$616.2M
Q2 24
$6.3M
$730.4M
Q1 24
$9.5M
$840.4M
Total Debt
ARTNA
ARTNA
DNA
DNA
Q4 25
$176.4M
Q3 25
Q2 25
Q1 25
Q4 24
$178.7M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ARTNA
ARTNA
DNA
DNA
Q4 25
$249.9M
$508.6M
Q3 25
$248.8M
$559.8M
Q2 25
$244.9M
$613.0M
Q1 25
$241.7M
$647.4M
Q4 24
$239.2M
$716.1M
Q3 24
$238.3M
$797.9M
Q2 24
$234.4M
$833.1M
Q1 24
$232.0M
$987.3M
Total Assets
ARTNA
ARTNA
DNA
DNA
Q4 25
$851.2M
$1.1B
Q3 25
$833.9M
$1.2B
Q2 25
$819.3M
$1.2B
Q1 25
$808.9M
$1.3B
Q4 24
$798.6M
$1.4B
Q3 24
$796.0M
$1.5B
Q2 24
$783.1M
$1.6B
Q1 24
$798.6M
$1.6B
Debt / Equity
ARTNA
ARTNA
DNA
DNA
Q4 25
0.71×
Q3 25
Q2 25
Q1 25
Q4 24
0.75×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARTNA
ARTNA
DNA
DNA
Operating Cash FlowLast quarter
$10.5M
$-47.7M
Free Cash FlowOCF − Capex
$-7.9M
$-47.7M
FCF MarginFCF / Revenue
-28.1%
-142.8%
Capex IntensityCapex / Revenue
65.4%
0.0%
Cash ConversionOCF / Net Profit
2.53×
TTM Free Cash FlowTrailing 4 quarters
$-18.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARTNA
ARTNA
DNA
DNA
Q4 25
$10.5M
$-47.7M
Q3 25
$11.0M
$-31.6M
Q2 25
$7.9M
$-40.3M
Q1 25
$11.0M
$-51.5M
Q4 24
$6.7M
$-42.4M
Q3 24
$10.7M
$-103.5M
Q2 24
$6.9M
$-84.4M
Q1 24
$12.6M
$-89.3M
Free Cash Flow
ARTNA
ARTNA
DNA
DNA
Q4 25
$-7.9M
$-47.7M
Q3 25
$-3.3M
Q2 25
$-7.9M
$-40.3M
Q1 25
$560.0K
$-59.1M
Q4 24
$-8.3M
$-56.1M
Q3 24
$-1.9M
$-118.6M
Q2 24
$-2.6M
$-111.4M
Q1 24
$3.7M
$-96.0M
FCF Margin
ARTNA
ARTNA
DNA
DNA
Q4 25
-28.1%
-142.8%
Q3 25
-10.7%
Q2 25
-27.8%
-81.2%
Q1 25
2.2%
-122.4%
Q4 24
-30.9%
-128.0%
Q3 24
-6.5%
-133.2%
Q2 24
-9.4%
-198.2%
Q1 24
15.0%
-252.9%
Capex Intensity
ARTNA
ARTNA
DNA
DNA
Q4 25
65.4%
0.0%
Q3 25
46.7%
0.0%
Q2 25
55.6%
0.1%
Q1 25
40.2%
15.8%
Q4 24
55.9%
31.3%
Q3 24
43.1%
16.9%
Q2 24
34.5%
48.1%
Q1 24
36.4%
17.7%
Cash Conversion
ARTNA
ARTNA
DNA
DNA
Q4 25
2.53×
Q3 25
1.58×
Q2 25
1.26×
Q1 25
2.02×
Q4 24
1.74×
Q3 24
1.56×
Q2 24
1.29×
Q1 24
2.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARTNA
ARTNA

Water Sales$22.3M80%
Other Utility Operating Revenue$3.8M14%
Non Utility Operating Revenue$1.9M7%

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

Related Comparisons